Detalhe da pesquisa
1.
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.
Breast Cancer Res
; 23(1): 79, 2021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344426
2.
Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility.
Int J Cancer
; 148(8): 1895-1909, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368296
3.
A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers.
BMC Med Res Methodol
; 21(1): 155, 2021 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34325649
4.
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Int J Cancer
; 144(8): 1962-1974, 2019 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30303537
5.
Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Breast Cancer Res
; 20(1): 28, 2018 04 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29665859
6.
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families.
Carcinogenesis
; 38(10): 994-1003, 2017 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28981872
7.
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
J Med Genet
; 53(5): 298-309, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26921362
8.
GENESIS: a French national resource to study the missing heritability of breast cancer.
BMC Cancer
; 16: 13, 2016 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26758370
9.
Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
Eur J Cancer
; 179: 76-86, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36509001
10.
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
Front Oncol
; 8: 490, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30430080